The aim of the present study was to investigate the effect of okra consumption on serum levels of lipid profiles and glycemic indices in Type 2 diabetic (T2D) patients. The present study was a randomized, double-blinded clinical trial, carried out in Kerman, Iran. Sixty T2D patients were randomized into intervention and control groups and received 10 g okra powder blended in 150 g conventional yogurt or conventional yogurt alone, along with dinner and lunch, for 8 weeks. Glycemic markers and lipid profile were assessed, as well as anthropometric measures, at the beginning and end of study. The findings showed that 8 weeks okra consumption resulted in a significant decrease in fasting plasma glucose (−15.61 ± 19.44 vs. −3.40 ± 24.78; p = .02), homeostatic model of assessment for insulin resistance (−1.17 ± 1.61 vs. −0.14 ± 1.64; p = .01), quantitative insulin sensitivity check index (0.01 ± 0.007 vs. 0.00 ± 0.01; p = .004), triacylglycerol (−22.30 ± 32.46 vs. −3.86 ± 30.57; p = .001), total cholesterol (−10.23 ± 10.36 vs. −2.03 ± 13.94; p = .004), low-density lipoprotein cholesterol (LDL-C; −8.15 ± 10.01 vs. −2.31 ± 9.37; p = .02), and LDL-C/high-density lipoprotein cholesterol (HDL-C) ratio (−0.28 ± 0.37 vs. −0.08 ± 0.24; p = .01). No significant difference was observed between groups in HDL-C, glycated hemoglobin, fasting insulin levels, and anthropometric measures. The present study suggests that okra consumption can elicit improvements in lipid profile, as well as glycemic markers, among T2D patients.

This study sought to summarize clinical evidence of sour tea (Hibiscus sabdariffa L.) administration on cardiovascular disease risk factors. PubMed, Scopus, Institute for Scientific Information Web of Science, and Google Scholar were systematically searched from inception to June 2019 to identify randomized clinical trials, which assessed the effect of sour tea consumption on lipid profiles, fasting plasma glucose, and blood pressure in adult populations. Mean and standard deviation for each parameter were extracted to calculate effect size. Cochrane Collaboration tools were used to evaluate risk of bias assessment. A total of seven randomized clinical trials consisting 362 participants were included in the meta-analysis. Pooled effect size demonstrated that sour tea consumption significantly reduces fasting plasma glucose (−3.67 mg/dl, 95% confidence interval, CI [−7.07, −0.27]; I 2 = 37%), systolic blood pressure (−4.71 mmHg, 95% CI [−7.87, −1.55]; I 2 = 53%), and diastolic blood pressure (−4.08 mmHg, 95% CI [−6.48, −1.67]; I 2 = 14%). Although no significant effect was observed on triacylglycerol, total cholesterol, and high-density lipoprotein cholesterolfollowing sour tea consumption, a trend toward a significant reduction was found in low-density lipoprotein cholesterol serum concentrations (p = 0.08). This systematic